|
| related topics |
| {operation, international, foreign} |
| {product, liability, claim} |
| {product, candidate, development} |
| {regulation, government, change} |
| {stock, price, share} |
| {cost, regulation, environmental} |
| {stock, price, operating} |
| {financial, litigation, operation} |
| {property, intellectual, protect} |
| {personnel, key, retain} |
| {competitive, industry, competition} |
| {regulation, change, law} |
| {product, market, service} |
|
|
Safety Issues with TYSABRI Could Significantly Affect our Growth.
Our Long-Term Success Depends Upon the Successful Development and Commercialization of Other Products from Our Research and Development Activities and External Growth Opportunities.
Competition in Our Industry and in the Markets for Our Products is Intense.
We are Subject to Risks Related to the Products that We Manufacture.
We Rely to a Large Extent on Third Parties in the Manufacturing of Our Products.
The Manufacture of Our Products is Subject to Government Regulation.
Royalty Revenues Contribute to Our Overall Profitability and Are Not Within Our Control.
Our Operating Results Are Subject to Significant Fluctuations.
Our Sales Depend on Payment and Reimbursement from Third Party Payors, and a Reduction in Payment Rate or Reimbursement Could Result in Decreased Use or Sales of Our Products.
We May Be Unable to Adequately Protect or Enforce Our Intellectual Property Rights or Secure Rights to Third Party Patents.
Legislative or Regulatory Changes Could Harm Our Business.
Failure to Comply with Government Regulations Regarding Our Products Could Harm Our Business.
Some of Our Activities may Subject Us to Risks under Federal and State Laws Prohibiting Kickbacks and False or Fraudulent Claims.
Failure to Prevail in Litigation or Satisfactorily Resolve a Third Party Investigation Could Harm Our Business.
Our Business Involves Environmental Risks.
We Rely Upon Key Personnel.
Future Transactions May Harm Our Business or the Market Price of Our Stock.
We are Subject to Market Risk.
Our Financial Position, Results of Operations and Cash Flows can be Affected by Fluctuations in Foreign Currency Exchange Rates.
We are Exposed to Risk of Interest Rate Fluctuations.
Volatility of Our Stock Price.
Full 10-K form ▸
|
|
| related documents |
| 892025--1/16/2007--MARTEK_BIOSCIENCES_CORP |
| 313143--5/25/2007--HAEMONETICS_CORP |
| 21665--2/27/2009--COLGATE_PALMOLIVE_CO |
| 874716--2/19/2010--IDEXX_LABORATORIES_INC_/DE |
| 10795--11/26/2008--BECTON_DICKINSON_&_CO |
| 1104280--12/3/2010--SANGUI_BIOTECH_INTERNATIONAL_INC |
| 874716--2/20/2009--IDEXX_LABORATORIES_INC_/DE |
| 892025--1/13/2006--MARTEK_BIOSCIENCES_CORP |
| 930184--3/2/2009--VALEANT_PHARMACEUTICALS_INTERNATIONAL |
| 929987--2/22/2006--GUIDANT_CORP |
| 742112--3/1/2007--INVACARE_CORP |
| 313143--5/27/2008--HAEMONETICS_CORP |
| 850693--2/26/2010--ALLERGAN_INC |
| 1110783--10/26/2007--MONSANTO_CO_/NEW/ |
| 850693--3/1/2007--ALLERGAN_INC |
| 10795--11/23/2007--BECTON_DICKINSON_&_CO |
| 742112--2/27/2009--INVACARE_CORP |
| 10795--11/30/2006--BECTON_DICKINSON_&_CO |
| 892025--12/28/2007--MARTEK_BIOSCIENCES_CORP |
| 926844--5/29/2008--RENHUANG_PHARMACEUTICALS_INC |
| 789868--4/2/2007--AMERICAN_DAIRY_INC |
| 10456--2/19/2009--BAXTER_INTERNATIONAL_INC |
| 850693--3/6/2006--ALLERGAN_INC |
| 811669--2/23/2007--UST_INC |
| 816284--2/20/2008--CELGENE_CORP_/DE/ |
| 885725--3/1/2006--BOSTON_SCIENTIFIC_CORP |
| 1006195--6/8/2009--MATRIXX_INITIATIVES_INC |
| 836429--10/12/2010--SYNERGETICS_USA_INC |
| 930184--3/16/2006--VALEANT_PHARMACEUTICALS_INTERNATIONAL |
| 873364--3/13/2006--CEPHALON_INC |
|